Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2019
Reporting Period: Third quarter ended September 30, 2019
Context: The filing serves to announce the Company's financial and operating results for the third quarter of 2019 via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the publication of Q3 2019 results.
Guidance, Outlook, and Risks
Management Commentary: The Company published a press release on November 8, 2019, detailing Q3 2019 results.
Legal Disclaimer: The information in this Current Report and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. Furthermore, this information shall not be incorporated by reference into any registration statement unless expressly set forth by specific reference.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q3 2019 financial figures, as they are not present in the 8-K cover text.
- Verify the Company's status as an emerging growth company (indicated as checked in the filing).
- Note that the financial data in this filing is not incorporated by reference into future registration statements unless explicitly cited.
- Confirm the trading symbol (INMB) and exchange (NASDAQ) for current market data.